The cost, which is confidential & was negotiated for all in all , 300 huge number of doses, is slightly lower than the $19.50 a shot the United States agreed to purchase a very first shipment of 100 million doses of the identical vaccine, in line with what Reuters reported in November.
The EU booklet dated Nov. 18 was circulated internally right after the EU announced its supply offer with Pfizer and its German partner BioNTech on Nov. 11.
The EU drug regulator is actually anticipated to determine on Monday on acceptance for the Pfizer vaccine following the shot was authorised in a number of countries, like Britain and also the United States.
On Thursday Belgian say secretary on your budget Eva De Bleeker released on Twitter a dining room table with price tags Belgium will spend pharmaceutical companies for their COVID-19 vaccines. She retracted the content shortly after publishing.
In this table the Pfizer vaccine was suggested as costing Belgium 12 euros ($14.6) a dose, top many to think that was the entire cost agreed by way of the EU.
Other vaccines in the table were furthermore shown with rates lower than rates disclosed by EU solutions.
“There is , obviously , a full fee and a price upon delivery,” an EU official involved in talks with vaccine creators told Reuters when made to clarify the difference between the Belgian and EU prices.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality requirements, but pointed to what De Bleeker told the Belgian parliament previous week. In that public hearing, De Beeker stated Belgium’s budgeted costs were still partial.
Underneath EU prior purchase deals for COVID-19 vaccines, the bloc concurs initial payments with companies to secure doses before they are approved. After approvals, EU governments are able to pay the remainder to get reserved doses.
The EU hasn’t revealed the initial transaction agreed with Pfizer.
Nevertheless, it mentioned in October which it paid about 1 billion euros inside downpayments to AstraZeneca, Sanofi and Johnson & Johnson for their shots, with an additional 1.45 billion euros budgeted for upfront payments to Pfizer BioNTech, Curevac and Moderna.
It has since agreed supply deals with all six companies and it is negotiating a seventh agreement with Novavax.